15,000 Shares in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Bought by Caption Management LLC

Caption Management LLC purchased a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the fourth quarter, HoldingsChannel.com reports. The fund purchased 15,000 shares of the company’s stock, valued at approximately $32,000.

Several other hedge funds have also bought and sold shares of the stock. Lynx1 Capital Management LP increased its holdings in shares of Allogene Therapeutics by 75.3% in the fourth quarter. Lynx1 Capital Management LP now owns 10,874,723 shares of the company’s stock worth $23,163,000 after purchasing an additional 4,672,349 shares during the last quarter. Foresite Capital Management VI LLC purchased a new position in Allogene Therapeutics during the 4th quarter valued at approximately $7,345,000. Gilead Sciences Inc. bought a new stake in Allogene Therapeutics in the 4th quarter worth approximately $2,464,000. Dimensional Fund Advisors LP raised its holdings in shares of Allogene Therapeutics by 30.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,561,626 shares of the company’s stock worth $7,586,000 after acquiring an additional 831,146 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of Allogene Therapeutics by 1,732.2% during the 4th quarter. BNP Paribas Financial Markets now owns 849,658 shares of the company’s stock valued at $1,810,000 after acquiring an additional 803,284 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Analyst Ratings Changes

ALLO has been the topic of several research reports. Citizens Jmp upgraded shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target on the stock in a research report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a report on Friday, March 14th. HC Wainwright lowered their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, March 19th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a research note on Friday, March 14th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Allogene Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $9.29.

Insider Activity

In related news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the completion of the sale, the chief executive officer now owns 5,276,569 shares in the company, valued at $10,342,075.24. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 61,757 shares of company stock valued at $115,873. 24.30% of the stock is currently owned by company insiders.

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $1.20 on Thursday. The firm has a market capitalization of $261.35 million, a P/E ratio of -0.77 and a beta of 0.60. Allogene Therapeutics, Inc. has a 1-year low of $1.18 and a 1-year high of $3.78. The company’s 50-day moving average is $1.61 and its 200 day moving average is $1.99.

Allogene Therapeutics (NASDAQ:ALLO) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.06. Research analysts anticipate that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).